On-demand strategy as an alternative to conventionally scheduled post-transplant immunoadsorptions after ABO-incompatible kidney transplantation

被引:30
作者
Wilpert, Jochen
Geyer, Marcel
Pisarski, Przemyslaw
Drognitz, Oliver
Schulz-Huotari, Christian
Gropp, Anette
Goebel, Heike
Gerke, Peter
Teschner, Sven
Walz, Gerd
Donauer, Johannes
机构
[1] Univ Hosp, Div Renal, Freiburg, Germany
[2] Univ Hosp, Div Surg, Transplantat Unit, Freiburg, Germany
[3] Univ Hosp, Dept Transfus Med, Freiburg, Germany
[4] Univ Hosp, Dept Pathol, Freiburg, Germany
关键词
ABO-incompatible; IgG titer; immunoadsorption; indirect antiglobulin test; kidney transplantation;
D O I
10.1093/ndt/gfm460
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Since 2001, approximately 100 ABO-incompatible kidney transplantations have been performed in Europe. The standard protocol, employed by most transplant centres, uses rituximab and scheduled pre-emptive antigen-specific immunoadsorption on post-operative days 3, 6 and 9. Methods. Our centre has performed 22 ABO-incompatible kidney transplantations since 2004, using a different approach; like in Sweden, all patients received immunoadsorptions preoperatively, but instead of scheduling pre-emptive post-transplant immunoadsorptions, we submitted patients to immunoadsorptions post-operatively only, if their isoagglutinine titers ( IgG-Anti-A or -B) exceeded certain thresholds. These thresholds were greater than 1 : 8 in the first post-operative week and greater than 1 : 16 in the second post-operative week, respectively. Results. A shorter pre-operative length on dialysis, a blood-type constellation of donor A1/recipient 0 and 9a high initial starting-titer were identified as predictors for post-operative immunoadsorptions. Conclusion. Using this on-demand strategy, our data reveal that a titer-dependent protocol reduces costs at no additional risk for the patient.
引用
收藏
页码:3048 / 3051
页数:4
相关论文
共 7 条
[1]   ABO-incompatible kidney transplantation of an 8-yr-old girl with donor/recipient-constellation A1B/B [J].
Ahlenstiel, T ;
Offner, G ;
Strehlau, J ;
Pape, L ;
Froede, K ;
Ehrich, JHH ;
Schwarz, A ;
Heuft, HG ;
Klempnauer, J .
XENOTRANSPLANTATION, 2006, 13 (02) :141-147
[2]   ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a single center experience [J].
Donauer, J ;
Wilpert, J ;
Geyer, M ;
Schwertfeger, E ;
Kirste, G ;
Drognitz, O ;
Walz, G ;
Pisarski, P .
XENOTRANSPLANTATION, 2006, 13 (02) :108-110
[3]   A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation [J].
Gloor, JM ;
Lager, DJ ;
Fidler, ME ;
Grande, JP ;
Moore, SB ;
Winters, JL ;
Kremers, WK ;
Stegall, MD .
TRANSPLANTATION, 2005, 80 (11) :1572-1577
[4]   ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. [J].
Gloor, JM ;
Lager, DJ ;
Moore, SB ;
Pineda, AA ;
Fidler, ME ;
Larson, TS ;
Grande, JP ;
Schwab, TR ;
Griffin, MD ;
Prieto, M ;
Nyberg, SL ;
Velosa, JA ;
Textor, SC ;
Platt, JL ;
Stegall, MD .
TRANSPLANTATION, 2003, 75 (07) :971-977
[5]   Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan [J].
Takahashi, K ;
Saito, K ;
Takahara, S ;
Okuyama, A ;
Tanabe, K ;
Toma, H ;
Uchida, K ;
Hasegawa, A ;
Yoshimura, N ;
Kamiryo, Y .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (07) :1089-1096
[6]   ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab [J].
Tydén, G ;
Kumlien, G ;
Genberg, H ;
Sandberg, J ;
Lundgren, T ;
Fehrman, I .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (01) :145-148
[7]   Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab [J].
Tydén, G ;
Kumlien, G ;
Fehrman, I .
TRANSPLANTATION, 2003, 76 (04) :730-731